ClinicalTrials.gg
Not yet recruitingNCT07933835Updated Nov 12, 2026

A Study to Learn How Different Amounts of the Study Medicine Called PF-08166744 Are Tolerated and Act in Healthy Adults.

A Phase 1 interventional study of PF-08166744 and Placebo in Healthy Participants, sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08166744) in healthy adults. This is the first time PF-08166744 will be given to people.

This study is seeking participants who:

  • are 18 to 65 years old
  • are generally healthy
  • have a body mass index (BMI) of 16 to 32 kg/m² and weigh more than 50 kg. Participants will receive either PF-08166744 or placebo. A placebo does not have any medicine in it but looks like the medicine being studied. PF-08166744 or placebo will be given as a shot under the skin. In some study groups, it may be given directly into a vein. Participants will receive either a single dose or 3 doses, depending on the study group they join.

The Investigators will compare the experiences of people receiving study medicine with those receiving placebo. This will help researchers learn about the safety and effects of study medicine.

People receiving a single dose will take part in the study for about 12 to 20 weeks. Those receiving multiple doses will take part for about 22 weeks. During the study, participants will have study visits and tests. These will help check their health and measure the amount of study medicine in their blood.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy Participants
  • Single Ascending Dose
  • Multiple Ascending Dose
  • Healthy Adults
  • Pharmacokinetics
  • Safety
  • Tolerability
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants 18 to 65 years of age, inclusive.
  • Participants considered generally healthy based on medical evaluation.
  • (BMI) of 16 to 32 kg/m².
  • Body weight greater than 50 kg.
  • Participants must meet protocol-defined reproductive requirements.
  • Participants enrolled in multiple-dose cohorts must meet protocol-defined vaccination requirements.

Exclusion criteria

Exclusion Criteria:

  • Medical conditions that may increase the risk associated with study participation or interfere with study assessments.
  • Pre-existing conditions that may increase the risk of infection.
  • Protocol-defined active or inadequately treated infections.
  • History of protocol-specified allergic or anaphylactic reactions.
  • abnormalities identified during medical evaluation, including laboratory, vital sign, or assessments.
  • Protocol-prohibited prior/concomitant medications, vaccines, or products.
  • Pregnancy or breastfeeding, where applicable under protocol-defined reproductive criteria.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Arm 1: PF-08166744

    Participants in Part A will receive a single ascending dose of PF-08166744 by subcutaneous or intravenous administration according to the assigned cohort. Participants in Part B will receive multiple ascending subcutaneous doses of PF-08166744 according to the assigned cohort.

    Drug: PF-08166744

  • Placebo comparator
    Arm 2: Placebo

    Participants in Part A will receive a single dose of placebo by subcutaneous or intravenous administration according to the assigned cohort. Participants in Part B will receive multiple subcutaneous doses of placebo according to the assigned cohort.

    Drug: Placebo

Interventions

  • DrugPF-08166744

    Participants will receive a single dose of PF-08166744 by subcutaneous or intravenous administration.

  • DrugPlacebo

    Participants will receive a single dose of placebo by subcutaneous or intravenous administration.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127

  2. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127

  3. Number of Participants With Vital Sign Abnormalities

    Time frame: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127

  4. Number of Participants With Electrocardiogram (ECG) Abnormalities

    Time frame: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127

Secondary outcomes

  1. SAD (Part A): Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of PF-08166744

    Time frame: Day 1 through Day 113

  2. SAD (Part A): Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of PF-08166744

    Time frame: Day 1 through Day 113

  3. SAD (Part A): Maximum Observed Plasma Concentration (Cmax) of PF-08166744

    Time frame: Day 1 through Day 113

  4. SAD (Part A): Time to Maximum Observed Plasma Concentration (Tmax) of PF-08166744

    Time frame: Day 1 through Day 113

  5. SAD (Part A): Terminal Elimination Half-Life (t1/2) of PF-08166744

    Time frame: Day 1 through Day 113

  6. MAD (Part B): Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau) of PF-08166744

    Time frame: Day 1 through Day 127

  7. MAD (Part B): Maximum Observed Plasma Concentration (Cmax) of PF-08166744

    Time frame: Day 1 through Day 127

  8. MAD (Part B): Time to Maximum Observed Plasma Concentration (Tmax) of PF-08166744

    Time frame: Day 1 through Day 127

  9. MAD (Part B): Terminal Elimination Half-Life (t1/2) of PF-08166744

    Time frame: Day 1 through Day 127

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2028, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 12, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Jan 18, 2028
CompletionEst.
Jan 18, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07933835
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Jan 18, 2028 (estimated)
Completion
Jan 18, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion